With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...

We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations ...

Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

The cuts will shutter two major HIV vaccine research efforts, and a National Institutes of Health senior official said the ...

Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States.

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...

Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target.

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...